UBS Group
CLB icon

UBS Group’s Core Laboratories CLB Stock Holding History

UBS Group’s Portfolio CLB Stock Details CLB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q2 		– Sell
-12,100
Closed -$1.26M – 8516
2015
Q1 		$1.26M Buy
12,100
+12,000
+12,000% +$1.28M ﹤0.01% 3359
2014
Q4 		$12K Buy
+100
New +$13.1K ﹤0.01% 8212

Other funds holding CLB

AI
Ariel Investments Chicago, Illinois $8.93B AUM 29.58% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
DGI
Disciplined Growth Investors Minneapolis, Minnesota $4.89B AUM 33.85% 1-Year Est. Return
EARNEST Partners
EARNEST Partners Atlanta, Georgia $24.3B AUM 34.41% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
CAMG
CWA Asset Management Group Naples, Florida $3.28B AUM 34.07% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

UBS Group's CLB Position: Q1 2026 in Review

UBS Group increased its Core Laboratories (CLB) stake by 4.6% in Q1 2026, buying an estimated $342K and bringing the position to 431,653 shares worth $7.25M. The position accounts for ﹤0.01% of the portfolio, ranked #3685.

UBS Group first reported a position in CLB in Q4 2014 and has held it in 46 quarters since. 190 funds tracked by Wall St. Rank hold CLB as of Q1 2026.

  • UBS Group held 431,653 shares of Core Laboratories worth $7.25M as of Q1 2026.
  • UBS Group bought 19,138 Core Laboratories shares in Q1 2026, an estimated $342K.
  • Core Laboratories made up ﹤0.01% of UBS Group's portfolio in Q1 2026, its #3685 holding.
  • UBS Group first reported a position in Core Laboratories in Q4 2014 and has held it in 46 quarters since.
  • 190 funds tracked by Wall St. Rank held Core Laboratories as of Q1 2026.

Based on UBS Group's 13F filing for Q1 2026, filed 5 May 2026.